Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccination to Reduce Exacerbations in COPD Frequent Exacerbators
NCT07508644Phase 4Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2027
- Primary completion
- Jun 2030
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of GSK3003899A in chronic obstructive pulmonary disease (COPD), respiratory syncytial virus infection (RSV), sponsored by The Chinese University of Hong Kong. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
GSK3003899A
03
Conditions
chronic obstructive pulmonary disease (COPD)respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07508644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508644.